From the New York Times, it's the headlines.

I'm Tracy Mumford.

Today's Monday, May 4th.

Here's what we're covering.

A federal appeals court ruling on Friday has upended abortion access in the U.S.

And put the issue back in front of the Supreme Court.

Here's what to know about the case. It centers on the abortion pill Miffapristone.

Since 2021, the FDA has allowed medical providers to send that drug through the mail.

It made that change at the height of the pandemic when a lot of people couldn't get to the doctor.

After the Supreme Court overturned Roe v. Wade the next year,

telemedicine appointments for abortion pills became even more popular.

Patients in states with bans or restrictions on the procedure

turned to out-of-state providers.

And just in general, nationwide, abortion through telemedicine has become more and more common.

By one count, more than a quarter of all abortions in the first half of last year were provided that way.

But now, Louisiana has sued to stop that.

Claiming the practice has allowed patients to get around the state's near total abortion ban and put the state on the hook for Medicaid bills for women harmed by the drug.

On Friday, a federal appeals court ruled that while Louisiana's lawsuit is moving forward, the FDA must require patients to visit medical providers in person to get Miphypristone.

Two manufacturers of the drug filed an emergency request with the Supreme Court over the weekend,

asking the justices to step in and immediately restore full access.

One called the lawsuit a baseless attack on an essential medication.

More than 100 studies have found Miphypristone to be safe and effective. In the meantime,

...